Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30756612 | 0.89 | AAK1 (0.37) | AAK1METAP1GSK3BDYRK1ARORC | |
| SCHEMBL32667023 | 0.85 | AAK1 (0.36) | CNR2GAAAAK1GRM5RORC | |
| SCHEMBL32667206 | 0.84 | AAK1 (0.40) | CNR2GAAAAK1METAP1GRM5 | |
| SCHEMBL22498638 | 0.81 | ALDH1A1 (0.40) | GAAAAK1METAP1 | |
| SCHEMBL30755793 | 0.79 | NPC1 (0.40) | GAAAAK1METAP1 | |
| SCHEMBL30755819 | 0.79 | CNR2 (0.43) | CNR2AAK1 | |
| SCHEMBL24617872 | 0.78 | AAK1 (0.37) | AAK1METAP1GSK3BDYRK1A | |
| SCHEMBL22498359 | 0.78 | AAK1 (0.37) | GAAAAK1METAP1GSK3BDYRK1A | |
| SCHEMBL32667220 | 0.78 | TSHR (0.42) | CNR2AAK1METAP1GRM5CHEK1 | |
| SCHEMBL32667169 | 0.78 | AAK1 (0.40) | AAK1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | TYK2, ERBB2, ROS1 | CNR2 567/4885GAA 2592/4885AAK1 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.